OLR1 Genotype

Two people with identical cholesterol numbers can have very different artery walls a decade later. One reason is the receptor your blood vessels use to grab oxidized cholesterol particles and pull them inside the wall, where they start building plaque. The gene that makes this receptor comes in slightly different versions, and the version you inherited can quietly shift your odds of coronary disease, stroke, and even Alzheimer's.

OLR1 (oxidized LDL receptor 1) is the gene that codes for a protein called LOX-1, the main scavenger receptor that pulls damaged cholesterol into your artery walls. This test reads the specific variants you carry. Because the result is written in your DNA, it does not move with diet, exercise, or medication. You learn it once, then use it for life.

What This Test Actually Reads

OLR1 has several small genetic variations that researchers have studied. Some sit in regulatory regions of the gene (the 3'UTR, or three prime untranslated region, which is the tail end of the gene that controls how much receptor gets made). Others are coding changes, where a single letter swap alters the receptor protein itself. The most studied include rs1050283 (also called +1073 C/T) in the regulatory tail, rs11053646 (called K167N) in the coding region, and intron variants like IVS4-14 A>G that travel together as a single inherited block.

These variants matter because they change how the receptor behaves. Lab work on the 3'UTR variant shows it changes which proteins bind to the gene's regulatory tail, which in turn changes how much LOX-1 the gene produces. The K167N coding change shifts a single amino acid in the receptor. In the lab, the asparagine version of the receptor grabs oxidized cholesterol less tightly than the lysine version, which sounds protective. But the epidemiology tells a different story: the same variant that weakens binding in cell studies is the one linked to thicker carotid walls and higher stroke odds in human populations. Why a weaker-binding receptor associates with worse outcomes is an unresolved question in the field, and one reason this gene is treated as research-grade rather than clinical. The evidence below comes entirely from human studies of these specific variants.

Coronary Artery Disease and Heart Attack

In a study of white women, carriers of the 3'UTR T allele had about 67% higher odds of significant coronary narrowing compared to non-carriers, and the association held up after accounting for other risk factors. These same carriers also had higher levels of antibodies against oxidized LDL, suggesting the receptor was working overtime in their artery walls.

An Italian study of acute heart attack patients found an even stronger signal. People carrying the 3'UTR T variant were roughly 3.7 times as likely to have had a heart attack compared to those without it. Not every study finds this. A separate Italian coronary disease cohort and a small Turkish coronary disease cohort did not find clear differences between cases and controls for these variants, though the Turkish work did link the IVS4 G allele to higher LDL cholesterol and the Italian work tied the K167N variant to a larger number of blocked vessels in people who already had disease. A much larger replication attempt in the ADVANCE and ARIC studies, with more than 13,000 participants, also failed to confirm a link between OLR1 variants and coronary artery disease. Taken together, the picture is genuinely mixed.

What this means for you: OLR1 is one of many genetic factors that nudge coronary risk in either direction. A high-risk variant does not guarantee disease, and a protective variant does not exempt you. The signal is real but modest, and it lands on top of everything else you know about your lipids, blood pressure, and family history.

Carotid Plaque and Stroke

The K167N variant has the most consistent link to artery wall thickening and stroke. In a Dominican population, women carrying the variant were between 2.4 and 5.9 times as likely to have plaque in their carotid arteries, the major neck vessels feeding the brain. In men from the same group, the association did not appear. A separate Italian cohort of over 2,000 people found the opposite sex pattern for carotid wall thickness, with male carriers showing thicker artery walls than non-carriers.

A meta-analysis pulling together seven studies on ischemic stroke (the kind caused by a blocked vessel) found that carriers of the minor (less common) C allele at the K167N site were about 33% more likely to have had a stroke than non-carriers. This is a moderate signal that has held up across multiple populations.

Metabolic Risk

In a small Italian study of people with metabolic syndrome, those carrying two copies of the IVS4-14 G variant had higher fasting glucose, more signs of insulin resistance, and more protein leaking into their urine (a sign of early kidney stress). A separate Iranian study of coronary patients found that people with two copies of a different OLR1 promoter variant (rs3736234) had higher body mass index and higher triglycerides than non-carriers.

These findings suggest that OLR1 variants do not just affect what happens at the artery wall. They may also shape how your body handles glucose and fat, though the metabolic data is thinner than the cardiovascular data and comes from smaller cohorts.

Alzheimer's Disease

OLR1 shows up in brain research because LOX-1 sits on the cells lining the brain's small blood vessels, where it pulls in oxidized cholesterol and helps drive the inflammation and vascular damage that may contribute to Alzheimer's pathology. Several case-control studies have linked the 3'UTR C allele to higher Alzheimer's risk, sometimes only in people who also carry the APOE e4 variant (a separate, well-established Alzheimer's risk gene). A meta-analysis estimated that carriers of the 3'UTR C allele had about 23% higher odds of Alzheimer's than non-carriers.

Pathology work in donated brain tissue suggests one possible reason. People carrying two copies of the C variant who did not also carry APOE e4 had higher deposits of beta-amyloid (the protein that builds up in Alzheimer's brains) in the small blood vessels of their frontal cortex, a pattern called cerebral amyloid angiopathy. This points to a vascular clearance problem rather than a direct effect on neurons. Not every study agrees. A large family-based study found no link between this variant and Alzheimer's overall, suggesting the real-world effect is small and probably depends on other genes you carry.

Why This Is Not a Tier 1 Genetic Test

OLR1 genotyping is a research-grade test, not a guideline-backed clinical screen. Most associations come from observational case-control studies, often in single populations, with effect sizes that are modest and sometimes inconsistent across ethnic groups. No clinical trial has shown that knowing your OLR1 status changes outcomes, and no professional society currently recommends OLR1 testing for routine cardiovascular or dementia risk assessment.

This does not make the test useless. It means you should treat the result as one input into a broader picture, not as a verdict. If you carry a high-risk variant, the right response is to tighten the modifiable risks you already know about: lipids, blood pressure, glucose, body composition, sleep, and inflammation. If you carry a low-risk variant, that is mildly reassuring but does not exempt you from the same fundamentals.

How This Result Fits Into Your Larger Workup

Because OLR1 codes for a receptor that grabs oxidized cholesterol, the test sits naturally alongside other markers that capture the same biology. If you carry a high-risk variant, the highest-yield companion tests are apolipoprotein B (a count of all the cholesterol particles that can lodge in your artery walls), lipoprotein(a) (an inherited cholesterol particle that drives early heart disease), and high-sensitivity C-reactive protein (a marker of the low-grade inflammation that feeds plaque growth). Together, these tell you whether the receptor your genes built is being fed a steady stream of substrate.

What to Do If You Carry a Risk Variant

A high-risk OLR1 result is a reason to act earlier and more aggressively on the levers you control, not a reason to retest the gene. The decision pathway is straightforward. First, get a full lipid workup including apolipoprotein B and lipoprotein(a) if you have not already. Second, add a marker of vascular inflammation like high-sensitivity C-reactive protein. Third, consider earlier imaging of your arteries (a coronary artery calcium scan or carotid ultrasound) if you have any combination of family history, abnormal lipids, or other risk factors.

If you also carry an APOE e4 allele, the case for tighter cardiovascular and cognitive risk management gets stronger, because the two genes appear to interact in some studies. A consultation with a preventive cardiologist or a clinician comfortable with cardiovascular genetics is reasonable, especially if the OLR1 result lands alongside other risk signals.

One Test, Lifelong Information

You do not need to retest your OLR1 genotype. The result is fixed at conception and stays the same whether you read it at 30, 50, or 70. What changes over your lifetime is the value of the information, because every additional risk factor you accumulate (rising blood pressure, climbing apolipoprotein B, advancing age) makes your inherited tendency more relevant. The retest cadence to pay attention to is for the downstream markers (lipids, inflammation, blood pressure, glucose), not the gene itself.